Valuation: Akeso, Inc.

Capitalization 104B 120B 15.3B 13.05B 11.97B 11.33B 20.99B 1,464B 21.19B 143B 55.49B 694B 57.4B 56.19B 2,413B P/E ratio 2026 *
809x
P/E ratio 2027 * 73.2x
Enterprise value 98.37B 113B 14.48B 12.35B 11.33B 10.72B 19.87B 1,386B 20.06B 135B 52.55B 658B 54.35B 53.2B 2,285B EV / Sales 2026 *
19.1x
EV / Sales 2027 * 12.7x
Free-Float
78.36%
Yield 2026 *
-
Yield 2027 * 0.01%
1 day-0.99%
1 week+1.72%
Current month-4.27%
1 month-5.93%
3 months+23.57%
6 months+13.64%
Current year+15.04%
1 week 126.1
Extreme 126.1
138.8
1 month 120.4
Extreme 120.4
156
Current year 93.65
Extreme 93.65
156
1 year 73.1
Extreme 73.1
179
3 years 26.45
Extreme 26.45
179
5 years 11.5
Extreme 11.5
179
10 years 11.5
Extreme 11.5
179
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 58 15/11/2019
Corporate Officer/Principal 50 15/11/2019
Chief Executive Officer 59 18/03/2012
Director TitleAgeSince
Director/Board Member 53 31/03/2020
Director/Board Member 57 15/11/2019
Director/Board Member 63 31/03/2020
Change 5d. change 1-year change 3-years change Capi.($)
-0.99%+1.72%+54.12%+196.47% 15.45B
+1.01%+2.02%+40.77%+89.57% 50.65B
+1.48%+0.71%+86.81%+62.75% 48.58B
+0.34%-5.73%+0.96%-8.70% 23.6B
+11.66%-17.15%+78.24%+512.14% 22.52B
+1.94%-2.49%+45.89%-27.68% 17.47B
+3.22%+0.29%+29.83%-40.31% 16.06B
+1.55%+11.60%-20.91%+884.42% 14.48B
+2.58%-0.04%+43.55% - 13.38B
-0.50%+11.98%+36.74%+155.61% 12.49B
Average +2.23%-1.42%+39.60%+202.70% 23.47B
Weighted average by Cap. +2.19%-1.82%+46.54%+160.73%

Financials

2026 *2027 *
Net sales 5.16B 5.95B 760M 648M 594M 563M 1.04B 72.73B 1.05B 7.08B 2.76B 34.5B 2.85B 2.79B 120B 7.65B 8.81B 1.13B 960M 881M 834M 1.54B 108B 1.56B 10.49B 4.08B 51.11B 4.22B 4.14B 178B
Net income 184M 212M 27.09M 23.11M 21.19M 20.06M 37.17M 2.59B 37.53M 252M 98.28M 1.23B 102M 99.51M 4.27B 1.45B 1.67B 213M 182M 167M 158M 293M 20.41B 295M 1.99B 774M 9.68B 800M 783M 33.63B
Net Debt -5.52B -6.36B -813M -693M -636M -602M -1.12B -77.82B -1.13B -7.57B -2.95B -36.91B -3.05B -2.99B -128B -6.63B -7.64B -976M -833M -764M -723M -1.34B -93.44B -1.35B -9.1B -3.54B -44.32B -3.66B -3.59B -154B
Logo Akeso, Inc.
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
Employees
3,761
Date Price Change Volume
12/05/26 130.00 $ -0.99% 3,913,037
11/05/26 131.30 $ -2.01% 5,787,648
08/05/26 134.00 $ -2.83% 5,574,055
07/05/26 137.90 $ +3.30% 9,639,961
06/05/26 133.50 $ +4.46% 13,764,200
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
112.79CNY
Average target price
150.59CNY
Spread / Average Target
+33.52%

Quarterly revenue - Rate of surprise